Granted Patent
B2
US 12,370,166 · App. 17/816,950 · Granted Jul 29, 2025
Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
Assignee:
Epitracker, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipolar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.
Claims (32)
1. A method of treatment, management, or amelioration of a condition selected from the group consisting of aggression, anxiety, anxiety disorders, attention-deficit hyperactivity disorder, bipolar disorder, brain damage, cholestatic pruritis, depression, cocaine abuse, drug-seeking behavior, facial erythema associated with rosacea, glaucoma, hyperactive bladder, hypertension, impulsivity, mental disorders, mental conditions, migraines, nasal congestion, sinus congestion, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pathological gambling, schizophrenia, spinal cord injury, tardive dyskinesia, tics with Tourette's syndrome, and behavioral problems with Tourette's syndrome, the method comprising:
administering to a subject in need thereof, an effective amount of pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof.
2. The method of claim 1 , wherein a body concentration of pentadecanoylcarnitine of from 1 μM to 20 μM is achieved in the subject.
3. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered.
4. The method of claim 1 , wherein from 0.1 mg to 50 mg, per 1 kg of body weight, of the pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof is administered.
5. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof is administered once per day.
6. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof is in a unit dosage form comprising from 0.01 mg to 10000 mg, of the pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof.
7. The method of claim 1 , wherein the condition is selected from the group consisting of aggression, anxiety, anxiety disorders, attention-deficit hyperactivity disorder, cholestatic pruritis, depression, cocaine abuse, drug-seeking behavior, glaucoma, hyperactive bladder, hypertension, impulsivity, mental disorders, mental conditions, migraines, obsessive-compulsive disorders, opioid-induced respiratory depression, pathological gambling, schizophrenia, tardive dyskinesia, tics with Tourette's syndrome, and behavioral problems with Tourette's syndrome.
8. The method of claim 1 , wherein the condition is selected from anxiety disorders, attention-deficit hyperactivity disorder, depression, brain damage, glaucoma, tardive dyskinesia, cholestatic pruritis, tics with Tourette's syndrome, and behavioral problems with Tourette's syndrome.
9. The method of claim 1 , wherein the condition is selected from aggression, anxiety, bipolar disorder, depression, drug-seeking behavior, hypertension, migraines, opioid-induced respiratory depression, and schizophrenia.
10. The method of claim 1 , wherein the condition is selected from anxiety, depression, aggression, and impulsivity.
11. The method of claim 1 , wherein the condition is selected from facial erythema associated with rosacea, nasal congestion, and sinus congestion.
12. The method of claim 1 , wherein the condition is selected from cocaine abuse, pathological gambling, obsessive-compulsive disorder, and schizophrenia.
13. The method of claim 1 , wherein the condition is obsessive-compulsive disorder.
14. The method of claim 1 , wherein the condition is hyperactive bladder or depression.
15. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered as a dietary supplement.
16. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered in a unit dosage form.
17. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered in a tablet, a capsule, an encapsulated pill, a gelcap pill, a dispensable form of an oral or injectable liquid suspension or solution, a spray, an aerosol, powder, or granules.
18. The method of claim 1 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is isolated from natural sources, semi-synthetic, synthetic, or any mixture thereof.
19. A method of supporting appetite, memory, mood, renal health, sexuality, sociability, or weight loss, the method comprising:
administering to a subject in need thereof, an effective amount of pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof.
20. The method of claim 19 , wherein a body concentration of pentadecanoylcarnitine of from 1 μM to 20 μM is achieved in the subject.
21. The method of claim 19 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered.
22. The method of claim 19 , wherein from 0.1 mg to 50 mg, per 1 kg of body weight, of the pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof is administered.
23. The method of claim 19 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt or solvate thereof is administered once per day.
24. The method of claim 19 , wherein pentadecanoylcarnitine or or pharmaceutically acceptable salts, solvates, or stereoisomers thereof is in a unit dosage form comprising from 0.01 mg to 10000 mg, of the pentadecanoylcarnitine or pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof.
25. The method of claim 19 , wherein the method supports appetite, mood, renal health, sexuality, or sociability.
26. The method of claim 19 , wherein the method supports appetite, sexuality, or sociability.
27. The method of claim 19 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered as a dietary supplement.
28. The method of claim 19 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered in a unit dosage form.
29. The method of claim 19 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is administered in a tablet, a capsule, an encapsulated pill, a gelcap pill, a dispensable form of an oral or injectable liquid suspension or solution, a spray, an aerosol, powder, or granules.
30. The method of claim 19 , wherein pentadecanoylcarnitine or a pharmaceutically acceptable salt thereof is isolated from natural sources, semi-synthetic, synthetic, or any mixture thereof.
Continuity (3)
Provisional Application
63340710
· May 11, 2022
Provisional Application
63275353
· Nov 3, 2021
References Cited (400)
US 4252159A
· Maki
· 1981
[cited by applicant]
US 4718430A
· Holzer
· 1988
[cited by applicant]
US 4985015A
· Obermann et al.
· 1991
[cited by applicant]
US 5318521A
· Slettenmark
· 1994
[cited by applicant]
US 5449688A
· Wahl et al.
· 1995
[cited by applicant]
US 5465728A
· Phillips
· 1995
[cited by applicant]
US 5741816A
· Tsujihara et al.
· 1998
[cited by applicant]
US 6214875B1
· Yang
· 2001
[cited by applicant]
US 6384252B1
· Pageat
· 2002
[cited by applicant]
US 6441036B1
· Berge
· 2002
[cited by applicant]
US 6544541B1
· Zahradka
· 2003
[cited by applicant]
US 7012053B1
· Barnabas et al.
· 2006
[cited by applicant]
US 7375135B2
· Najib-Fruchart et al.
· 2008
[cited by applicant]
US 7651845B2
· Doyle et al.
· 2010
[cited by applicant]
US 8030348B2
· Sampalis
· 2011
[cited by applicant]
US 8088825B2
· Berge et al.
· 2012
[cited by applicant]
US 8106093B2
· Roe
· 2012
[cited by applicant]
US 8251904B2
· Zivitz et al.
· 2012
[cited by applicant]
US 8759558B2
· Holmeide et al.
· 2014
[cited by applicant]
US 8827957B2
· Searle et al.
· 2014
[cited by applicant]
US 9282760B2
· Bryhn et al.
· 2016
[cited by applicant]
US 9295637B2
· Perricone
· 2016
[cited by applicant]
US 9561206B2
· Venn-Watson
· 2017
[cited by applicant]
US 9662306B2
· Venn-Watson
· 2017
[cited by applicant]
US 9687461B2
· Venn-Watson
· 2017
[cited by applicant]
US 9707199B2
· Venn-Watson
· 2017
[cited by applicant]
US 9713600B2
· Venn-Watson
· 2017
[cited by applicant]
US 20020156351A1
· Sagel
· 2002
[cited by applicant]
US 20030203004A1
· Kelm et al.
· 2003
[cited by applicant]
US 20030203042A1
· Cook
· 2003
[cited by applicant]
US 20060154833A1
· Katou et al.
· 2006
[cited by applicant]
US 20060269495A1
· Popp et al.
· 2006
[cited by applicant]
US 20060275294A1
· Omoigui
· 2006
[cited by applicant]
US 20090318369A1
· Paige et al.
· 2009
[cited by applicant]
US 20110098358A1
· Fujimoto et al.
· 2011
[cited by applicant]
US 20110182943A1
· Kanwar et al.
· 2011
[cited by applicant]
US 20110190702A1
· Stumber
· 2011
[cited by applicant]
US 20110201558A1
· Roe et al.
· 2011
[cited by applicant]
US 20120072236A1
· Atkin
· 2012
[cited by applicant]
US 20140303228A1
· Lawton et al.
· 2014
[cited by applicant]
US 20160195558A1
· Venn-Watson et al.
· 2016
[cited by applicant]
US 20190054052A1
· Shchepinov
· 2019
[cited by applicant]
US 20190240181A1
· Venn-Watson
· 2019
[cited by applicant]
US 20210046034A1
· Venn-Watson
· 2021
[cited by applicant]
US 20210346419A1
· Venn-Watson
· 2021
[cited by applicant]
US 20230201153A1
· Venn-Watson
· 2023
[cited by applicant]
US 20230293491A1
· Venn-Watson
· 2023
[cited by applicant]
US 20230381127A1
· Venn-Watson
· 2023
[cited by applicant]
US 20240016773A1
· Venn-Watson
· 2024
[cited by applicant]
US 20240277649A1
· Venn-Watson et al.
· 2024
[cited by applicant]
US 20240307336A1
· Venn-Watson
· 2024
[cited by applicant]
CA 2337484A1
· 2001
[cited by applicant]
CN 1939332A
· 2007
[cited by applicant]
CN 102327368A
· 2012
[cited by applicant]
DE 2615061
· 1977
[cited by applicant]
DE 102010010666A1
· 2011
[cited by applicant]
EP 1000071A1
· 2000
[cited by applicant]
EP 1020179A2
· 2000
[cited by applicant]
EP 3301090A1
· 2018
[cited by applicant]
JP S60172925
· 1985
[cited by applicant]
JP S61015809A
· 1986
[cited by applicant]
JP S62012716
· 1987
[cited by applicant]
JP S63099063
· 1988
[cited by applicant]
JP H06172168A
· 1994
[cited by applicant]
JP 2003160486A
· 2003
[cited by applicant]
JP 2004115438A
· 2004
[cited by applicant]
JP 2005523331A
· 2005
[cited by applicant]
JP 2008255022A
· 2008
[cited by applicant]
JP 2008540393
· 2008
[cited by applicant]
JP 2010260833A
· 2010
[cited by applicant]
JP 2011528350A
· 2011
[cited by applicant]
JP 2014080432A
· 2014
[cited by applicant]
JP 2015010067A
· 2015
[cited by applicant]
JP 2016504403
· 2016
[cited by applicant]
JP 6029668B2
· 2016
[cited by applicant]
JP 2017200910A
· 2017
[cited by applicant]
JP 2017536879A
· 2017
[cited by applicant]
KR 20170087813A
· 2017
[cited by applicant]
KR 201701009096A
· 2017
[cited by applicant]
KR 102087634B1
· 2020
[cited by applicant]
WO WO199626647
· 1996
[cited by applicant]
WO WO199632850
· 1996
[cited by applicant]
WO WO1999001103
· 1999
[cited by applicant]
WO WO1999002485
· 1999
[cited by applicant]
WO WO2000040217
· 2000
[cited by applicant]
WO WO2004057982
· 2004
[cited by applicant]
WO WO2004069240
· 2004
[cited by applicant]
WO WO2005099483
· 2005
[cited by applicant]
WO WO2005120485
· 2005
[cited by applicant]
WO WO2006038063
· 2006
[cited by applicant]
WO WO2006117668
· 2006
[cited by applicant]
WO WO2007002365
· 2007
[cited by applicant]
WO WO2007100435
· 2007
[cited by applicant]
WO WO2008114732
· 2008
[cited by applicant]
WO WO2010123930
· 2010
[cited by applicant]
WO WO2012001336
· 2012
[cited by applicant]
WO WO2012069790
· 2012
[cited by applicant]
WO WO2013007700
· 2013
[cited by applicant]
WO WO2014108573
· 2014
[cited by applicant]
WO WO2014179341
· 2014
[cited by applicant]
WO WO2015110977
· 2015
[cited by applicant]
WO WO2015140545
· 2015
[cited by applicant]
WO WO2015157514
· 2015
[cited by applicant]
WO WO2016111843
· 2016
[cited by applicant]
WO WO2017186928
· 2017
[cited by applicant]
WO WO2018157013
· 2018
[cited by applicant]
WO WO2019212196A1
· 2019
[cited by applicant]
WO WO2019222254
· 2019
[cited by applicant]
WO WO2019226572
· 2019
[cited by applicant]
WO WO2019226572A1
· 2019
[cited by examiner]
WO WO2020146263
· 2020
[cited by applicant]
WO WO2020154173
· 2020
[cited by applicant]
Anxiety Disorders. Cleveland Clinic: 2020. my.clevelandclinic.org/health/diseases/ 9536-anxiety-disorders (Year: 2020).
[cited by examiner]
Staner, Luc. Sleep and Anxiety Disorders. Dialogues in Clinical Neuroscience—vol. 5 . No. 3 . 2003 (Year: 2003).
[cited by examiner]
Bianchi Current Opinion in Cell Biology 2020, 63:135-143 (Year: 2020).
[cited by examiner]
https://www.cancer.org/cancer/risk-prevention.html (Year: 2023).
[cited by examiner]
Adachi et al., “Effect of the glyceride of pentadecanoic acid on energy metabolism in hair follicles”. Int J Cosmetic Sci. Jun. 1993;15(3): 125-131.
[cited by applicant]
Agius et al., “The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective”. Int J Mol Sci. May 3, 2020;21(9): 3240 in 19 pages.
[cited by applicant]
Aglago et al., Association between serum phospholipid fatty acid levels and adiposity in Mexican women. J Lipid Res. Jul. 1, 2017;58(7): 1462-1470.
[cited by applicant]
Ali et al., “Recent advances and limitations of mTOR inhibitors in the treatment of cancer”. Cancer Cell Int. Dec. 2022;22(1): 284 in 16 pages.
[cited by applicant]
Ananthakrishnan et al., Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. Feb. 1, 2009;15(2): 182-189.
[cited by applicant]
Anisimov et al., “Metformin slows down aging and extends life span of female SHR mice”. Cell Cycle Sep. 1, 2008;7(17): 2769-2773.
[cited by applicant]
Bartzokis et al., Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging. Mar. 1, 2007;28(3): 414-423.
[cited by applicant]
Barzilai et al., “Metformin as a tool to target aging”. Cell Metab. Jun. 14, 2016;23(6): 1060-1065.
[cited by applicant]
Baum et al., Drug utilization in the U.S.—1985: Seventh annual review. Rockville, MD: Food and Drug Administration, Center for Drugs and Biologies. Dec. 1986.; TOC in 4 pages.
[cited by applicant]
Beanes et al., Down-regulation of decorin, a transforming growth factor-beta modulator, is associated with scarless fetal wound healing. J Pediatr Surg. Nov. 1, 2001;36(11): 1666-1671.
[cited by applicant]
Berg E.L. Phenotypic chemical biology for predicting safety and efficacy. Drug Disc Today Technol. Mar. 1, 2017;23: 53-60.
[cited by applicant]
Bettcher et al., Increases in pro-inflammatory chemokine, MCP-1, are related to decreases in memory over time. Frontiers in aging neuroscience. Feb. 13, 2019; 11:25.
[cited by applicant]
Bielec et al., Homologies between human and dolphin chromosomes detected by heterologous chromosome painting. Cytogen Genome Res. 1998;81(1): 18-25.
[cited by applicant]
Biong et al., Intake of milk fat, reflected in adipose tissue fatty acids and risk of myocardial infarction: a case-control study. Eur J Clin Nutr. Feb. 2006;60(2): 236-244.
[cited by applicant]
Bishop et al., Heptadecanoic acid is not a key mediator in the prevention of diet-induced hepatic steatosis and insulin resistance in mice. Nutrients Apr. 24, 2023;15(9): 2052 in 14 pages.
[cited by applicant]
Blagosklonny M.V., Aging and immortality: Quasi-programmed senescence and its pharmacologic inhibition. Cell cycle. Sep. 15, 2006;5(18): 2087-2102.
[cited by applicant]
Blagosklonny M.V., Rapamycin for longevity: opinion article. Aging Oct. 15, 2019;11(19): 8048-8067.
[cited by applicant]
Blagosklonny M.V., “Cell senescence, rapamycin and hyperfunction theory of aging”. Cell Cycle Jul. 18, 2022;21(14): 1456-1467.
[cited by applicant]
Bridle et al., “Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways”. Transplantation Oct. 2009;15(10): 1315-1324.
[cited by applicant]
Browner et al., “The genetics of human longevity”. Am J Med. Dec. 1, 2004;117(11): 851-860.
[cited by applicant]
Brydges et al., Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain, Behavior, and Immunity. May 1, 2022;102: 42-52 (available Aug. 5, 2021).
[cited by applicant]
Budczies et al., “Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue—a GC-TOFMS based metabolomics study”. BMC Genomics Dec. 2012;13(1): 334 in 11 pages.
[cited by applicant]
Chaib et al., “Cellular senescence and senolytics: the path to the clinic”. Nat Med. Aug. 2022;28(8): 1556-1568.
[cited by applicant]
Chaudhari et al., Increased mitochondrial fusion allows the survival of older animals in diverse C. elegans longevity pathways. Nat Commun. Aug. 3, 2017;8(1): 182 in 16 pages.
[cited by applicant]
Cheng et al., “Metformin's mechanisms in attenuating hallmarks of aging and age-related disease”. Aging Dis. Jul. 7, 2022;13(4): 970-986.
[cited by applicant]
Coccia et al., IL-1B mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J Exp Med. Aug. 27, 2012;209(9): 1595-1609.
[cited by applicant]
Crimmins E.M., “Lifespan and healthspan: past, present, and promise”. The Gerontologist Dec. 1, 2015;55(6): 901-911.
[cited by applicant]
De Martinis et al., Allergy and aging: an old/new emerging health issue. Aging and Dis. Apr. 2017;8(2): 162-175.
[cited by applicant]
De Mello et al., “Serum levels of plasmalogens and fatty acid metabolites associate with retinal microangiopathy in participants from the Finnish Diabetes Prevention Study”. Nutrients Dec. 14, 2021;13(12): 4452 in.
[cited by applicant]
Deng et al., Cross-talk between mitochondrial fusion and the hippo pathway in controlling cell proliferation during drosophila development. Genetics Aug. 1, 2016; 203(4): 1777-1788.
[cited by applicant]
Devito et al., “Extending human lifespan and longevity: a symposium report”. Ann N Y Acad Sci. Jan. 2022;1507(1): 70-83 [publ. online Sep. 8, 2021}.
[cited by applicant]
Djousse et al., Serum individual nonesterified fatty acids and risk of heart failure in older adults. Cardiology Feb. 25, 2021;146(3): 351-358.
[cited by applicant]
Dornan et al., Odd chain fatty acids and odd chain phenolic lipids (alkylresorcinols) are essential for diet. J Am Chem Soc. Aug. 2021;98(8): 813-824.
[cited by applicant]
Dugan et al., Inflammaging as a target for healthy ageing. Age and Ageing. Feb. 1, 2023;52(2): afac328 in 15 Pages.
[cited by applicant]
Ediriweera et al., “Odd-chain fatty acids as novel histone deacetylase 6 HDAC6) inhibitors”. Biochimie Jul. 11, 2021;186: 147-156.
[cited by applicant]
Ehninger et al., “Longevity, aging and rapamycin”. Cell Mol Life Sci. Nov. 2014;71(22): 4325-4346.
[cited by applicant]
Farage et al., Characteristics of the aging skin. Adv Wound Care. Feb. 1, 2013;2(1): 5-10.
[cited by applicant]
Fonteh et al., Human cerebrospinal fluid fatty acid levels differ between supernatant fluid brain-derived nanoparticle fractions, and are altered in Alzheimer's disease. PloS One. Jun. 23, 2014;9(6): e100519 in 14 pages.
[cited by applicant]
Franceschi et al., Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. J Gerontol. Jun. 2014; 69(suppl 1): S4-S9.
[cited by applicant]
Fu et al., Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature. Sep. 4, 2003;425(6953): 90-93.
[cited by applicant]
Fu et al., Pentadecanoic acid promotes basal and insulin-stimulated glucose uptake in C2C12 myotubes. Food Nutr Res. 2021;65: 4527 in 9 pages.
[cited by applicant]
Galdiero et al., Pentadecanoic acid against Candida albicans-Klebsiella pneumoniae biofilm: Towards the development of an anti-biofilm coating to prevent polymicrobial infections. Res Microbiology. Nov. 1, 2021;172(7-8)…
[cited by applicant]
Garay R.P., “Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu”. Expert Opin Investig Drugs Jul. 3, 2021;30(7): 749-758.
[cited by applicant]
Gibson et al., Cooperative care. The time has come. JONA: J Nurs Admin. Mar. 1, 1987;17(3): 19-21.
[cited by applicant]
Giulani A., The application of principal component analysis to drug discovery and biomedical data. Drug Disc Today. Jul. 1, 2017;22(7): 1069-1076.
[cited by applicant]
Gonzalez-Freire et al., “The road ahead for health and lifespan interventions”. Ageing Res Rev. May 1, 2020;59:101037 in 46 pages.
[cited by applicant]
Gosmanova et al., “Effect of metformin containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus”. Am J Med Sci. Sep. 1, 2008;336(3): 241-247.
[cited by applicant]
Gregg et al., Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: A modelling study. Lancet Diab Endocrinol. Nov. 1, 2014;2(22): 867-874.
[cited by applicant]
Groarke et al., “Aging and hematopoiesis”. Clin Geriatr Med. Aug. 1, 2019;35(3): 285-293.
[cited by applicant]
Gunn-Moore et al., Alzheimer's disease in humans and other animals: a consequence of postreproductive life span and longevity rather than aging. Alzheimer's & Dementia. Feb. 1, 2018;14(2): 195-204.
[cited by applicant]
Harrison et al., “Acarbose, 17—α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males”. Aging Cell Apr. 2014;13(2): 273-282.
[cited by applicant]
Hayaishi O., Molecular mechanisms of sleep-wake regulation: roles of prostaglandins D2 and E2. FASEB J. Aug. 1991;5(11): 2575-2581.
[cited by applicant]
Hirose et al., Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain. Legal Med. Mar. 1, 2003;5: S360-366.
[cited by applicant]
Hori et al., “Serum sphingomyelin species profile is altered in hematologic malignancies”. Clin Chim Acta Mar. 1, 2021;514: 29-33.
[cited by applicant]
Huang et al., “Circulating saturated fatty acids and incident type 2 diabetes: A systematic review and meta-analysis”. Nutrients May 1, 2019;11(5): 998 in 20 pages.
[cited by applicant]
Hulbert A.J. “On the importance of fatty acid composition of membranes for aging”. J Theor Biol. May 21, 2005;234(2): 277-288.
[cited by applicant]
Imamura et al., “Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies”. PLoS Med. Oct. 10, 2018;15(10): e1002670 in 18 pages.
[cited by applicant]
Iwakura et al., The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immun Rev. Dec. 2008;226(1): 57-79.
[cited by applicant]
Jee et al., “Clinical relevance of glycerophospholipid, sphingomyelin and glutathione metabolism in thepathogenesis of pharyngolaryngeal cancer in smokers: the Korean Cancer Prevention Study—II”. Metabolomics Nov. 2016;…
[cited by applicant]
Jiao et al., Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in South Texas Hispanics. Cancer Epide., Biomark & Prev. Sep. 1, 2021;30(9): 1643-1651.
[cited by applicant]
Jimenez-Cepeda et al., Dietary intake of fatty acids and its relationship with FEV1/FVC in patients with chronic obstructive pulmonary disease. Clin Nutr. ESPEN. Feb. 1, 2019;29: 92-96.
[cited by applicant]
Jing et al., Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrin. Feb. 5, 2018;461: 256-264.
[cited by applicant]
Justice et al., “Frameworks for proof-of-concept clinical trials of interventions that target fundamental aging processes”. J Gerontol A Biol Sci Med Sci. Nov. 1, 2016;71(11): 1415-1423.
[cited by applicant]
Justice et al., “Development of clinical trials to extend healthy lifespan”. Cardiovasc Endocrinol Metab. Dec. 2018;7(4): 80-83.
[cited by applicant]
Kaestner et al., “The potential of erythrocytes as cellular aging models”. Cell Death Differ. Sep. 2017;24(9): 1475-1477.
[cited by applicant]
Kaikkonen et al., “Associations of serum fatty acid proportions with obesity, insulin resistance, blood pressure and fatty liver: the cardiovascular risk in young Finns study”. J Nutr Apr. 2021;151(4): 970-978.
[cited by applicant]
Kaur et al., “Essential fatty acids as functional components of foods—a review”. J Food Sci Technol. Oct. 2014;51: 2289-2303.
[cited by applicant]
Khaw et al., Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study. PLoS Med. Jul. 3, 2012;9(7): e1001255 in 12 pages.
[cited by applicant]
Khwaja et al., “Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors”. Drug Safety Jul. 1, 2021;16(2): 122-128.
[cited by applicant]
Kirkham T.C., Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol. Sep. 1, 2005;16(5-6): 297-313.
[cited by applicant]
Kobayashi et al., New directions in cancer and aging: State of the science and recommendations to improve the quality of evidence on the intersection of aging with cancer control. Cancer. May 1, 2022;128(9): 1730-1737.
[cited by applicant]
Kritchevsky et al., “Testing the geroscience hypothesis: early days”. J Gerontol A Biol Sci Med Sci. Jan. 1, 2020;75(1): 99-101 [publ. online Dec. 13, 2019].
[cited by applicant]
Kruchinina et al., “Erythrocyte membrane fatty acids as the potential biomarkers for detection of early-stage and progression of colorectal cancer”. Ann Oncol. Jun. 1, 2018;29(Suppl 5): v52.
[cited by applicant]
Kurotani et al., “Even- and odd-chain saturated fatty acids in serum phospholipids are differentially associated with adipokines”. PLoS One May 26, 2017;12(5): e0178192 in 14 pages.
[cited by applicant]
Lankinen et al., “Plasma fatty acids as predictors of glycaemia and type 2 diabetes”. Diabetologia Nov. 2015;58: 2533-2544.
[cited by applicant]
Lee et al., A current review of molecular mechanisms regarding osteoarthritis and pain. Gene Sep. 25, 2013;527(2): 440-447.
[cited by applicant]
Li et al., Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor. Bioorg Med Chem Lttrs. Sep. 15, 2022;72: 128881 in 6 pages.
[cited by applicant]
Li et al., “Extraction, purification, and elucidation of six ginkgo homologs from Ginkgo biloba sarcotesta and evaluation of their anticancer activities”. Molecules Nov. 11, 2022;27(22): 7777 in 15 pages.
[cited by applicant]
Liang et al., “Biomarkers of dairy fat intake and risk of cardiovascular disease: a systematic review and meta analysis of prospective studies”. Crit Rev Food Sci Nutr. May 3, 2018;58(7): 1122-1130.
[cited by applicant]
Liechty K.W., Diminished interleukin-8 (IL-8) production in the fetal wound healing response. J Surg Res. Jun. 1, 1998;77(1): 80-84.
[cited by applicant]
Lim et al., The global impact of hepatic fibrosis and end-stage liver disease. Clinics in Liver Dis. Nov. 1, 2008;12(4): 733-746.
[cited by applicant]
Lin et al., Effects of the mTOR inhibitor Rapamycin on monocyte-secreted chemokines. BMC Immunol. Dec. 2014;15(1): 1-9.
[cited by applicant]
Lin et al., Efficacy and safety of topical mechanistic target of rapamycin inhibitors for facialangiofibromas in patients with tuberous sclerosis complex: a systematic review and network meta-analysis. Biomedicines Mar.…
[cited by applicant]
Lipschitz et al., The anemia of senescence. Am J Hematol. Aug. 1981;11(1): 47-54.
[cited by applicant]
Longo et al., “Interventions to slow aging in humans: are we ready?” Aging Cell Aug. 2015;14(4): 497-510.
[cited by applicant]
Lyu et al., Association between anemia and 3-year all-cause mortality among oldest old people in longevity areas in China. Zhonghua Liuxingbingxue Zazhi. Jul. 1, 2015;36(7): 682-686.
[cited by applicant]
Manca et al., Circulating fatty acids and endocannabinoide-related mediator profiles associated to human longevity. GeroScience. Aug. 2021;43(4): 1783-1798.
[cited by applicant]
Martin-Montalvo et al., “Metformin improves healthspan and lifespan in mice”. Nat Commun. Jul. 30, 2013;4(1): 2192 in 23 pages.
[cited by applicant]
Matthan et al., Spillover effects of a family-based childhood weight-management intervention on parent nutrient biomarkers and cardiometabolic risk factors. Curr Dev Nutrition Feb. 2022;6(2): 152 in 41 pages.
[cited by applicant]
McArtor et al., Extending multivariate distance matrix regression with an effect size measure and the asymptotic null distribution of the test statistic. Psychometrika. Dec. 2017;82: 1052-1077.
[cited by applicant]
Millner et al., “Lipid players of cellular senescence”. Metabolites Aug. 21, 2020;10(9): 399 in 17 pages.
[cited by applicant]
Monjan et al., Incidence of chronic insomnia associated with medical and psychosocial factors: an epidemiologic study among older persons. Sleep Res. Jun. 1996;25: 108.
[cited by applicant]
Moskalev et al., “Targeting aging mechanisms: pharmacological perspectives”. Trends Endocrinol Metab. Apr. 1, 2022;33:266-280.
[cited by applicant]
Murphy et al., The origin of human chromosome 1 and its homologs in placental mammals. Genome Res. Aug. 1, 2003;13(8): 1880-1888.
[cited by applicant]
Nadon et al., “NIA interventions testing program: investigating putative aging intervention agents in a genetically heterogeneous mouse model”. EBioMedicine Jul. 1, 2017;21: 3-4.
[cited by applicant]
Niedernhofer et al., Molecular pathology endpoints useful for aging studies. Age Res Rev. May 1, 2017;35: 241-249.
[cited by applicant]
Novelle et al., Metformin: A hopeful promise in aging research. CSH Persp Med. Mar. 1, 2016;6(3): a025932 in 13 pages.
[cited by applicant]
Pamplona et al., Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radical Biol Med. Oct. 15, 2008;45(8): 1159-1166.
[cited by applicant]
Paolisso et al., Low insulin resistance and preserved B-cell function contribute to human longevity but are not associated with TH-INS genes. Exp Gerontol. Dec. 1, 2001; 37(1):147-156.
[cited by applicant]
Patel et al., Prevalence and impact of pain among older adults in the United States: Findings from the 2011 National Health and Aging Trends Study. Pain Dec. 1, 2013;154(12): 2649-2657.
[cited by applicant]
Perreault et al., PPARδ agonism for the treatment of obesity and associated disorders: Challenges and opportunities. PPAR Res. 2008;2008: Article ID125387; in 9 pages.
[cited by applicant]
Perrone et al., Selective COX01 inhibition: A therapeutic target to be reconsidered. Curr Med Chem. Nov. 1, 2010;17(32): 3769-3805.
[cited by applicant]
Qi et al., “High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis”. Sci Rep. Jun. 3, 2021;11(1): 11805 in 10 pages.
[cited by applicant]
Ricciardelli et al., Pentadecanal and pentadecanoic acid coatings reduce biofilm formation of
[cited by applicant]
Roh et al., A clinical study of pentadecanoic glyceride (LHOP) on male pattern alopecia. J Korean Soc Clin Pharma Thera. Dec. 1, 1998;6(2): 199-206.
[cited by applicant]
Salive et al., “Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status”. J Am Geriat Soc. May 1992:40(5): 489-496.
[cited by applicant]
Salvatore et al., “Metformin: an old drug against old age and associated morbidities”. Diab Res Clin Prac. Feb. 1, 2020;160: 108025 in 11 pages.
[cited by applicant]
Santaren et al., “Serum pentadecanoic acid (15:0), a short-term marker of dairy food intake, is inversely associated with incident type 2 diabetes and its underlying disorders”. Am J Clin Nutr. Dec. 1, 2014;100(6): 1532…
[cited by applicant]
Sawh et al., Dairy fat intake, plasma pentadecanoic acid, and plasma iso-heptadecanoic acid are inversely associated with liver fat in children. J Ped Gastroent Nutr. Apr. 4, 2021;72(4): e90 in 18 pages.
[cited by applicant]
Schork et al., “Does modulation of an epigenetic clock define a geroprotector?” Adv Geriatr Med Res. Mar. 29, 2022;4(1): e220002 in 11 pages.
[cited by applicant]
Sgnoc et al., Age-related aspects of cutaneous wound healing: a mini review. Gerontol. 2013;59(2): 159-164.
[cited by applicant]
Shamburek et al., Disorders of the digestive system in the elderly. New Engl J Med. Feb. 15, 1990;322(7): 438-443.
[cited by applicant]
Singh et al., MCP-1: Function, regulation and involvement in disease. Int Immunopharm. Dec. 1, 2021;101: 107598 in 9 pages.
[cited by applicant]
Smedman et al., “Pentadecanoic acid in serum as a marker of intake of milk fat: relations between intake of milk fat and metabolic risk factors”. Am J Clin Nutr. Jan. 1, 1999;69(1): 22-29.
[cited by applicant]
Smith et al., “Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice”. BMC Microbiol. Dec. 2019;19(1): 1-6.
[cited by applicant]
Soboleva et al., “Fatty acids of the lipid fraction of erythrocyte membranes and intensity of lipid peroxidation in iron deficiency”. Bull Exp Biol Med. Jun. 1994;117: 600-603.
[cited by applicant]
Sorrenti et al., “Immunomodulatory and antiaging mechanisms of resveratrol, rapamycin, and metformin: focus on mTOR and AMPK signaling networks”. Pharmaceuticals Jul. 23, 2022;15(8): 912 in 20 pages.
[cited by applicant]
Soukas et al., “Metformin as anti-aging therapy: is it for everyone?” Trends Endocrinol Metab. Oct. 1, 2019;30(10): 745-755.
[cited by applicant]
To et al., “Pentadecanoic acid, an odd-chain fatty acid, suppresses the stemness of MCF-7/SC humanbreast cancer stem-like cells through JAK2/STAT3 signaling”. Nutrients Jun. 3, 2020;12(6): 1663 in 20 pages.
[cited by applicant]
To et al., “Effects of combined pentadecanoic acid and tamoxifen treatment on tamoxifen resistance in MCF-7/SC breast cancer cell”. Int J Mol Sci. Sep. 26, 2022;23(19): 11340 in 20 pages.
[cited by applicant]
Tsoukalas et al., Application of metabolomics Part II: Focus on fatty acids and their metabolites in healthy adults. Int J Mol Med. Jan. 1, 2019;43(1): 233-242.
[cited by applicant]
Vaarhorst et al., Lipid metabolism in long-lived families: the Leiden Longevity Study. Age. Jun. 2011;33(2): 219-227.
[cited by applicant]
Venn-Watson et al., “Modified fish diet shifted serum metabolome and alleviated chronic anemia in bottlenose dolphins (
[cited by applicant]
Venn-Watson et al., Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?. Scientific Rep. May 18, 2020;10(1): 1-4.
[cited by applicant]
Venn-Watson et al., A 25-y longitudinal dolphin cohort supports that long-lived individuals in same environment exhibit variation in aging rates. PNAS Aug. 25, 2020;117(34): 20950-20958.
[cited by applicant]
Venn-Watson et al., “Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems”. PL…
[cited by applicant]
Venn-Watson et al., Pentadecanoylcarnitine is a newly discovered endocannabinoid with pleiotropicactivities relevant to supporting physical and mental health. Sci Rep. Aug. 23, 2022;12(1): 13717 in 11 pages.
[cited by applicant]
Vézina et al., “Rapamycin (AY-22, 989), a new antifungal antibiotic”—Part I. J Antibio. 1975;28(10): 721-726.
[cited by applicant]
Vitiello M.V., Sleep disorders and aging: understanding the causes. J Gerontol. 1997 Jul. 1, 1997;52(4): M189-M191.
[cited by applicant]
Wagner et al., Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care Jul. 1, 2006;29(7): 1471-1477.
[cited by applicant]
Wang et al., Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell. Apr. 18, 2003;113(2): 159-170.
[cited by applicant]
Warensjö et al., “Estimated intake of milk fat is negatively associated with cardiovascular risk factors and does not increase the risk of a first myocardial infarction. A prospective case-control study”. Br J Nutr. Apr…
[cited by applicant]
Webster et al., “Target of rapamycin inhibitors (sirolimus and everolimus) for primaryimmunosuppression of kidney transplant recipients: a systemic review and meta-analysis of randomized trials”. Transplantation May 15,…
[cited by applicant]
Wolf et al., “The MalR type regulator AcrC is a transcriptional repressor of acarbose biosynthetic genes in
[cited by applicant]
Wu et al., “Extension of life span by acarbose: is it mediated by the gut microbiota”? Aging Dis. Jul. 7, 2022;13(4): 1005-1014.
[cited by applicant]
Xu et al., “Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage”. Thorax Apr. 1, 2018;73(4): 308-310.
[cited by applicant]
Xu et al., Cross-sectional associations of adipokines and abdominal fat distribution with aging in men. The Aging Male. Dec. 4, 2020;23(5): 1576-1582.
[cited by applicant]
Vasto et al., Inflammatory networks in ageing, age-related diseases, and longevity. Mech Ageing and Dev. Jan. 1, 2007;128(1): 83-91.
[cited by applicant]
Ye et al., A pharmacological network for lifespan extension in Caenorhabditis elegans. Aging cell. Apr. 2014;13(2): 206-215.
[cited by applicant]
Yoo et al., “An overview of rapamycin: from discovery to future perspectives”. J Indus Microbiol Biotech. May 1, 2017;44(4-5): 537-553.
[cited by applicant]
Yoo et al., Fatty acids in non-alcoholic steatohepatitis: : Focus on pentadecanoic acid. PloS One. Dec. 15, 2017;12(12): e0189965 in 15 pages.
[cited by applicant]
Yousefzadeh et al., Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans. Aging cell. Apr. 2018;17(2): e12706 in 7 pages.
[cited by applicant]
Zapala et al., Multivariate regression analysis of distance matrices for testing associations between gene expression patterns and related variables. Proc Nat Acad Scie. Dec. 19, 2006;103(51): 19430-19435.
[cited by applicant]
Zapala et al., Statistical properties of multivariate distance matrix regression for high-dimensional data analysis. Front Genetics. Sep. 27, 2012;3: 190 in 10 pages.
[cited by applicant]
Zhai et al., Anemia status and its relevant factors among elderly people aged above 80 years old in longevity areas in China. Chinese J of Prev Med. Feb. 1, 2010;44(2):115-118.
[cited by applicant]
Zheng et al., Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPI…
[cited by applicant]
Zheng et al., Changes in plasma phospholipid fatty acid profiles over 13 years and correlates of change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study. Am J Clin Nutr. Jun. 1, 2019;109(6): 1…
[cited by applicant]
Zhu et al., Synthesis and inhibitory activities against colon cancer cell growth and proteasome of alkylresorcinols. J Agric Food Chem. Sep. 5, 2012;60(35): 8624-8631.
[cited by applicant]
Zhu et al., A prospective study and longitudinal study of plasma phospholipid saturated fatty acid profile in relation to cardiometabolic markers and the risk of gestational diabetes. Am J Clin Nutr. Jun. 1, 2018;107(6)…
[cited by applicant]
Zhuang et al., Saturated fatty acid intake is associated with total mortality in a nationwide cohort study. J Nutr. Jan. 1, 2019;149(1): 68-77.
[cited by applicant]
Greenberg et al., “Omega-3 fatty acid supplementation during pregnancy”. Rev Obstet Gynecol. 2008;1(4): 162-169.
[cited by applicant]
Mihalik et al., “Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity”. Obesity Sep. 2010;18(9): 1695-1700.
[cited by applicant]
Venn-Watson et al., Physiology of aging among healthy, older bottlenose dolphins (
[cited by applicant]
Venn-Watson et al., “Hemochromatosis and fatty liver disease: building evidence for insulin resistance in bottlenose dolphins (
[cited by applicant]
Venn-Watson et al., “Blood-Based Indicators of Insulin Resistance and Metabolic Syndrome in Bottlenose Dolphins (
[cited by applicant]
Venn-Watson et al., “Increased Dietary Intake of Saturated Fatty Acid Heptadecanoic Acid (C17:0) Associated with Decreasing Ferritin and Alleviated Metabolic Syndrome in Dolphins”, PLoS ONE, 2016, 10(7):e0132117 in 17 p…
[cited by applicant]
International Search Report and Written Opinion dated Nov. 17, 2022 for PCT/US2022/039166.
[cited by applicant]
Abdullah et al., “Recommended dairy product intake modulates circulating fatty acid profile in healthy adults: a multi-centre cross-over study”, Br J Nutr. 113(3):435-444.
[cited by applicant]
Adams et al., “Hemochronatosis and iron-overload screening in a racially diverse population.” New Engl J Med. 2005, 352(17):1769-1778.
[cited by applicant]
Adams et al., “A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation”, J Hepatol. 2011, 55(2):453-458.
[cited by applicant]
Ahmad et al., “Interaction of Osteopontin with IL-18 in Obese Individuals: Implications for Insulin Resistance”. PLoS ONE 2013, 8(5):e63944 in 9 pages.
[cited by applicant]
Akbar et al., Alterations in Hepatic FGF21, Co-Regulated Genes, and Upstream Metabolic Genes in Response to Nutrition, Ketosis and Inflammation in Peripartal Holstein Cows, PLoS One 2015, 10(10):e0139963 in 16 pages.
[cited by applicant]
Akhter, J. MD; Asthma-cure, 2017, https://www.scientificamerican.com/article/can-asthma-be-cured-what/ in 7 pages.
[cited by applicant]
Aksenov et al., “Metabolite Content Profiling of Bottlenose Dolphin Exhaled Breath”, Anal Chem 2014, 86(21):10616-10624.
[cited by applicant]
Aleshin et al. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: review and novel hypotheses. Neurochem Int. (2013) 63…
[cited by applicant]
Altamura et al., “Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis.” J Alzheimer's Dis. 2009, 16(4):879-895.
[cited by applicant]
Anderson et al., “Cholesterol and mortality: 30 years of follow-up from the Framingham Study.” JAMA (1987) 257(16):2176-2180.
[cited by applicant]
Angulo et al., “Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease”. Gastroenterology. 2015, 149(2):389-397.
[cited by applicant]
Ballatore et al., “Carboxylic Acid (Bio) Isosteres in Drug Design”. ChemMedChem. 2013, 8(3):385-395.
[cited by applicant]
Barba et al., Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J Cell Mol Med. 2008. 12(5a): 1477-1485.
[cited by applicant]
Barcellini et al., “Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia”. Disease Markers (2015) Article ID 635670 in 7 pages.
[cited by applicant]
Barish et al., “PPARδ: a dagger in the heart of the metabolic syndrome”, J Clin Invest. (2006) 116(3): 590-597.
[cited by applicant]
Barros et al., “Prey and feeding patterns of resident bottlenose dolphins (
[cited by applicant]
Bartke et al., “Bioactive sphingolipids: metabolism and function”. J Lipid Res. (2009) 50(Suppl): S91-S96.
[cited by applicant]
Batista et al., “Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding”, PLoS ONE. 2012, 7(5):e33643 in 7 pages.
[cited by applicant]
Beaton et al., “Treatment of Hyperferritinemia”, Ann Hepatol. 2012, 11(3):294-300.
[cited by applicant]
Benatar et al., “The effects of changing dairy intake on trans and saturated fatty acid levels—results from a randomized controlled study”. Nutr J. 2014, 13:32 in 10 pages.
[cited by applicant]
Berens-Mccabe et al., “Prey selection in a resident common bottlenose dolphin (
[cited by applicant]
Bettcher et al., “MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes”, Alzheimers Dement (Amst). 2016, 3:91-97.
[cited by applicant]
Bhargava et al., “Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation”, JCI Insight. 2017, 2(19): 1-13.
[cited by applicant]
Bialek et al., “Fatty acid composition and oxidative characteristics of novel edible oils in Poland”. CyTA—Journal of Food. Jan. 2, 2017;15(1): 1-8; (published online Jul. 13, 2016).
[cited by applicant]
Bogdanov et al., “Metabolomic profiling to develop blood biomarkers for Parkinson's disease”, Brain 2008. 131(2): 389-396.
[cited by applicant]
Bonomo et al., “Iron overload potentiates diet-induced hypercholesterolemia and reduces liver PPAR-α expression in hamsters”. J Biochem Mol Toxicol. (2012) 26(6): 224-229.
[cited by applicant]
Borodina et al., “The biology of ergothioneine, an antioxidant nutraceutical”. Nutri Res Reviews (2020) 33: 190-217.
[cited by applicant]
Bossù et al., “Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment”. Brain Behav Immun. 2008, 22(4):487-492.
[cited by applicant]
Calder et al., “n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases.” Am J Clin Nutr. 2006, 83(6 suppl):1505S-1519S.
[cited by applicant]
Calder P.C., “Long-chain polyunsaturated fatty acids and inflammation”, Scandinavian J Food Nutr. 2006, 50(S2):54-61.
[cited by applicant]
Camaschella C., “Iron-Deficiency Anemia”, New Engl J Med. (2015) 372(19):1832-1843.
[cited by applicant]
CAS Database Accession No. 1989:205056; “Relationship between structure and anticonvulsant activities of 2-substituted 3-pyrazolidinones”. Du et al., Jun. 10, 1989; 2 pages.
[cited by applicant]
Cater et al., “Behenic acid is a cholesterol-raising saturated fatty acid in humans.” Am J Clin Nutr. 2001, 73(1):41-44.
[cited by applicant]
Chebib et al., “Guanidino acids act as p1 GABAC receptor antagonists”. Neurochem Res. Apr. 23, 2009; 34(10): 1704-1711.
[cited by applicant]
Cheng et al., “Distinct Metabolomic Signatures are Associated with Longevity in Humans.”, Nat Commun. 2015, 6:6791 in 22 pages.
[cited by applicant]
Chiba et al., Topical application of PPARα (but not β/δ or γ) suppresses atopic dermatitis in NC/Nga mice. Allergy (2012) 67: 936-942.
[cited by applicant]
Choi et al., “Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study”. Arch Intern Med. 2005, 165(9):997-1003.
[cited by applicant]
Choi et al., The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cell. (2012) 33(3): 217-222.
[cited by applicant]
Colegrove K., Histomorphology of the bottlenose dolphin (
[cited by applicant]
Collino et al., “Metabolic Signatures of Extreme Longevity in Northern Italian Centenarians Reveal a Complex Remodeling of Lipids, Amino Acids, and Gut Microbiota Metabolism”. PLoS ONE. 2013, 8(3):e56564.
[cited by applicant]
Cordaro et al., “2-Pentadecyl-2-Oxazoline reduces neuroinflammatory environment in the MPTP Model of Parkinson Disease”. Mol Neurobiol. Dec. 2018;55(12): 9251-9266.
[cited by applicant]
Corso et al., Corso et al., “Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia”, Dement Geriatr Cogn Disord Extra. 2017, 7(1):143-159.
[cited by applicant]
Craik J., GLUT-1 mediation of rapid glucose transport in dolphin (
[cited by applicant]
Croes et al., Formation of a 2-methyl-branched fatty aldehyde during peroxisomal alpha-oxidation. FEBS Lett. 1997, 412(3):643.645.
[cited by applicant]
Cronet et al., “Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family”, Structure. 2001, 9(8):699-706.
[cited by applicant]
Crossno et al., “Rosiglitazone Attenuates Hypoxia-induced Pulmonary Arterial Remodeling”. Am J Physiol Lung Cell Mol Physiol. Apr. 2007;292(4): L885-L897.
[cited by applicant]
Cusi et al., “Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial”. Ann Intern Med. 2016, 165(5):305-315.
[cited by applicant]
Daak et al., “Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial”. Am J Clin Nutr. 2013, 97(1):37-44.
[cited by applicant]
Das Undurti N., “Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review”, J Adv Res. 2018, 11:43-55.
[cited by applicant]
Database WPI, “Pentadecanoic acid compound”, Clarivate Analytics, AN: 2017-637713, Clarivate Analytics, dated: Jul. 2017; 2 pages.
[cited by applicant]
Database WPI, “Immunosuppressive agent . . . ”, AN: 1994-238645, Clarivate Analytics, dated: 1994; 2 pages.
[cited by applicant]
Database WPI, “An effective Saururus chinensisrhizome part . . . ”, AN: 2012-B90946, Clarivate Analytics, dated: 2012; 2 pages.
[cited by applicant]
Database WPI, “An anti-aging composition . . . ”, AN: 2004-310751, Clarivate Analytics, dated: 2004; 2 pages.
[cited by applicant]
Diehl et al., “Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis”. N Engl J Med. 2017, 377(21):2063-2072.
[cited by applicant]
Di Paolo et al., “Linking Lipids to Alzheimer's Disease: Cholesterol and Beyond”, Nat Rev Neurosci. 2011, 12(5):284-296.
[cited by applicant]
Dongiovanni et al., “Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target”. J Hepatol. 2011, 55:920-932.
[cited by applicant]
Dursun et al., 2015, The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's d…
[cited by applicant]
Durzan D.J., Arginine, scurvy and Cartier's “tree of life”. J Ethnobio Ethnomed. 2009. 5(1): 1-16.
[cited by applicant]
Ekstedt et al., “Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.” Hepatology. 2015; 61(5): 1547-1554.
[cited by applicant]
Ellervik et al., “Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study”, Lancet 2001, 358(9291):1405-1409.
[cited by applicant]
Evans et al., “NAD+ metabolite levels as a function of vitamins and calorie restriction: evidence for different mechanisms of longevity.” BMC Chem Biol. 2010, 10:2 in 10 pages.
[cited by applicant]
Fargion et al., “Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis”. Am J Gastroenterol. 2001, 96(8):2448-2455.
[cited by applicant]
Favé et al., “Physicochemical properties of lipids: new strategies to manage fatty acid bioavailability”. Cell Mol Biol. 2004, 50(7):815-831.
[cited by applicant]
FDA Guidance for Industry. “Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.” U.S. Food and Drug Administration, Jul. 2005 in 30 pages.
[cited by applicant]
FDA (2017) FDA drug safety communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. Accessed Dec. 5, 2017 https://www.fda.gov/Drugs/DrugSafety/ucm576656.htm in …
[cited by applicant]
Fernandes et al., “Relationship between Acute Phase Proteins and Serum Fatty Acid Composition in Morbidly Obese Patients”, Dis Markers 2013, 35(2):104-112.
[cited by applicant]
Forman et al., “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ”, Proc Natl Acad Sci U.S.A., 1997, 94(9):4312-4317.
[cited by applicant]
Forouhi et al., “Differences in the Prospective Association Between Individual Plasma PhospholipidSaturated Fatty Acids and Incident Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study”, Lancet Diabetes Endocrinal, 201…
[cited by applicant]
Fujiwara et al., “Biology of Heme in mammalian Erythroid Cells and Related Disorders”. BioMed Res Int'l. (2015) Article ID 278536 in 9 pages.
[cited by applicant]
Gabrielsen et al., “Adipocyte iron regulates adiponectin and insulin sensitivity”. J Clin Invest. 2012, 122(10):3529-3540.
[cited by applicant]
Gao et al., “In vitro evaluation of dual agonists for PPARΓ/β from the flower of Edgeworthia gardneri (wall.) Meisn”. J Ethnopharma . . . Mar. 13, 2015;162: 14-19.
[cited by applicant]
Ghannadi et al., “An Investigation of the Analgesic and Anti-Inflammatory Effects of Nigella sativa Seed Polyphenols”, J Med Food. 2005, 8(4): 488-493.
[cited by applicant]
Gibson RA., “Australian fish—An excellent source of both arachidonic acid and ω-3 polyunsaturated fatty acids”, Lipids 1983, 18(11):743-752.
[cited by applicant]
Giunta et al., “Inflammaging as a prodrome to Alzheimer's disease”, J Neuroinflammation 2008, 5:51; 15 pages.
[cited by applicant]
Glauber et al., “Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus”, Ann Intern Med. 1988, 108(5):663-668.
[cited by applicant]
Goncalves et al., “Fenofibrate prevents skeletal muscle loss in mice with lung cancer”. PNAS. Jan. 23, 2018;115(4): E743-E752.
[cited by applicant]
Gonzalez-Covarrubias et al., “Lipidomics of familial longevity”. Aging Cell. 2013, 12(3):426-434.
[cited by applicant]
Gonzalez-Covarrubias V., “Lipidomics in longevity and healthy aging”. Biogerontology. 2013, 14(6):663-672.
[cited by applicant]
Ghosh et al., “PAI-1 in tissue fibrosis.” J Cell Physiol. (2011) 227(2):493-507.
[cited by applicant]
Grundy et al., “Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition”, Circulation. 2004, 109(3):433-…
[cited by applicant]
Gunstone et al. [Eds.], “A review of even-chain fatty acid metabolism and the role of arachidic acid (C20:0) and lignoceric acid (C24:0) in health and disease”, The Lipid Handbook, Gunstone et al. [Eds.] 3rd Edition, 20…
[cited by applicant]
Hallgren et al., “Lymphocyte phytohemagllutinin responsiveness, immunoglobulins and autoantibodies in aging humans.” J Immunol. (1973) 111:1101-1107.
[cited by applicant]
Hall et al., “Annual, seasonal and individual variation in hematology and clinical blood chemistry profiles in bottlenose dolphins (
[cited by applicant]
Hannun et al., “Principles of bioactive lipid signalling: lessons from sphingolipids”, Nat Rev Mol Cell Biol. 2008, 9(2):139-150.
[cited by applicant]
Hassanali et al., “Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat”, Diabetes Obes Metab. 2010, 12(2):139-14…
[cited by applicant]
Hebbel et al., A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis, Cardiovsc Hematol Disord Drug Targets (200() 9(4):271-291.
[cited by applicant]
Heneka et al., “Neuroinflammation in Alzheimer's Disease”, Lancet Neurol. 2015, 14(4):388-405.
[cited by applicant]
Hodge et al., “Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: Interpreting the role of linoleic acid.” Am J Clin Nutrition (2007) 86(1): 189-197.
[cited by applicant]
Hodson et al., “Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake”, Prog Lipid Res. 2008, 47:348-380.
[cited by applicant]